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palavras-chave 
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resumo 
 
 
Domínios que ligam nucleotideos cíclicos (CNBD) regulam muitas vias de 
sinalização em células procarióticas e eucarióticas. Os ligandos AMP cíclico ou 
GMP cíclico ligam-se a estes domínios e induzem uma alteração 
conformacional que é propagada ao domínio efector, como uma cinase ou um 
canal iónico. 
Os canais de potássio da família ether-a-go-go (EAG) estão envolvidos em 
muitos processos fisiológicos que incluem repolarização cardíaca e neuronal, 
proliferação tumoral e secreção de hormonas. Estes canais são tetraméricos e 
cada subunidade inclui seis hélices transmembranares e dominios 
citoplasmáticos em N- e C-terminal. O domínio em C-terminal tem homologia 
com domínios que ligam nucleotídeos cíclicos mas foi demonstrado que os 
canais EAG não são afectados por nucleotídeos e o domínio não liga 
nucleotideos. O objectivo deste projecto foi resolver a estrutura de um domínio 
C-terminal de um canal EAG por cristalografia de raios-X e compreender o seu 
papel funcional. Determinei a estrutura de um destes domínios à resolução de 
2,2 Å; a estrutura tem a topologia de um CNBD mas a cavidade de ligação 
apresenta várias diferenças relativamente à de domínios que ligam 
nucleotideos cíclicos. Mais ainda, os canais EAG são inibidos por calmodulina 
e há dois locais de ligação de calmodulina a seguir ao CNBD. A estrutura 
mostrou que um destes locais se encontra sobreposto com uma região do 
domínio levantando a possibilidade da calmodulina regular o canal através da 
alteração conformacional do domínio C-terminal dos canais EAG. Esta 
possibilidade começou a ser explorada com recurso a ensaios de cross-linking 
químico e espectroscopia de fluorescência. 
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abstract 
 
Cyclic nucleotide binding domains (CNBD) are regulatory domains that 
participate in many signaling pathways in prokaryotic and eukaryotic cells. The 
ligand cAMP or cGMP binds these domains and induces a conformational 
change that is propagated to an effector domain, like a kinase or an ion 
channel. 
The ether-a-go-go (EAG) potassium channel family is involved in 
important physiological roles that include cardiac and neuronal repolarization, 
tumor proliferation and hormone secretion. These channels are tetramers, 
where each subunit includes six transmembrane helices and N- and C-terminal 
cytoplasmic domains.  The C-terminal domain has strong homology to CNBDs 
but it has been demonstrated that EAG channels are not affected by cyclic 
nucleotides and that the domain does not bind nucleotides. The ultimate goal of 
this project was to solve the structure of an EAG family C-terminal domain by 
X-ray crystallography and to understand its functional role. I have determined 
the structure of one of these domains at 2.2 Å; the structure has the canonical 
CNBD fold but it shows a ligand pocket that has several differences relative to 
a cyclic nucleotide binding site. Furthermore, EAG currents are inhibited by 
calmodulin binding and there are two calmodulin binding sites C-terminal to the 
CNBD. The structure reveals that one of these sites overlaps with a region of 
the domain raising the possibility that calmodulin affects channel function by 
changing the EAG C-terminal domain conformation. I have conducted 
preliminary tests on this hypothesis by using biochemical cross-linking 
experiments and fluorescence spectroscopy. 
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Abbreviations 
cAMP and cGMP - cyclic adenosine monophosphate and cyclic guanosine 
monophosphate 
CCP4 - Collaborative Computational Project 4 
CNG - cyclic nucleotide-gated channel 
CNBD - cyclic nucleotide binding domain 
DNA - deoxyribonucleic acid 
DTSSP - 3,3´-dithiobis[sulfosuccinimidylpropionate] 
DTT - dithiothreitol 
EAG - ether à go-go 
EDTA- ethylenediaminetetraacetic acid 
EGS - ethylglycol bis(succinimidylsuccinate) 
ESRF - European Synchrotron Radiation Facility 
hCaM - human calmodulin 
HCN - hyperpolarization-activated cyclic nucleotide-modulated channel 
HEPES- 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IMAC - immobilized metal affinity chromatography 
IPTG - isopropyl β-D-1-thiogalactopyranoside 
kbp - kilo base pair 
LB - Luria-Bertania Broth 
MCS - multiple cloning site 
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mEAG - mouse eag 
MlotiK - Mesorhizobium loti K+ channel 
OD - optical density 
PEG- polyethylene glycol 
PCR - polymerase chain reaction 
PDB - Protein Data Bank 
PMSF- phenylmethanesulphonylfluoride 
SDS-PAGE- sodium dodecyl sulfate polyacrylamid gel electrophoresis 
Tris- tris(hydroxymethyl)aminomethane 
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Introduction 
Ion transport across biological membranes 
Biological membranes are mostly impermeable to polar or charged solutes. 
Transport of ions through lipid membranes must consequently be mediated by 
transmembrane proteins that prevent the contact of the ions with the hydrophobic 
interior of the phospholipidic bilayer. This transport can either occur by diffusion of an ion 
down its electrochemical gradient (facilitated diffusion) or against its electrochemical 
potential, with an associated energy cost (active transport) 1,2. 
These transport proteins can be classified as pumps, transporters or channels. 
Pumps are, for example, ATPases that use the energy from ATP hydrolysis to move ions 
against their electrochemical potential. Transporters are further divided into uniporters 
that move a single molecule down its gradient, and symporters and antiporters that 
couple the transport of one molecule uphill to another one downhill. Transport in 
channels occurs by facilitated diffusion; furthermore, channels can allow ion movement 
at much higher rates than any of the transport systems 1,2. 
Ion channels 
 Ion channels (calcium, sodium, chloride or potassium channels) are present in all 
eukaryotic cells’ plasma membranes and together with ion pumps are responsible for the 
maintenance of the resting membrane potential at ~-70mV. 
 Besides having rates of transport near the unrestricted diffusion (up to 108 ions/s), 
ion channels are not saturable, most of them show selectivity for particular ions and are 
gated, switching between open and closed states in response to a stimuli that can be 
membrane voltage or the  concentration of a ligand or ion. 
Gating domains (voltage sensors or ligand binding domains) transform a stimulus 
into pore opening. The basic function of a voltage sensor domain is to couple movement 
of protein charges to pore opening, in response to changes the membrane electric field. 
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In channels with six transmembrane segments the voltage sensor is located mostly on the 
fourth transmembrane helix (S4) and is composed of positively charged residues at every 
third position 3. In ligand-gated channels, the binding of a ligand (for example, cyclic 
nucleotide) will induce conformational changes that are transmitted to the pore region 
and favour the open state.  
EAG K+ channel family 
Ether à go-go (EAG) channels are voltage-gated potassium channels involved in 
many important physiological phenomena such as cardiac and neuronal repolarization, 
insulin secretion, cell differentiation and tumor growth. 
 The typical K+ channel is an assembly of four subunits (tetramer) surrounding a 
central pore with a four-fold symmetry, fig. 1B. It can have two or six transmembrane 
helices as well as cytoplasmic regulatory/gating domains 4,5. 
Potassium channels contain a highly conserved signature sequence in the pore 
region (GYG or GFG – selectivity filter) that forms the coordinating shell for potassium 
ions in the channel. This region is responsible for the high selectivity of K+ ion over the Na+ 
ion by a factor of over 1000 6. Mutation of these residues disrupts the channel’s ability to 
discriminate between K+ and Na+ ions 4,5 
The eag gene was first 
identified by a mutation that gave 
Drosophila melanogaster leg 
shaking behavior when under 
ether anesthesia, hence the name 
7. Using homology screens of 
cDNA libraries, three related gene 
subfamilies have been found – eag, 
erg (eag-related gene) and elk 
(eag-like K+ channel), fig. 1C. 
Fig. 1 - The EAG potassium channel family. A – Schematic 
representation of an α-subunit of an EAG channel, 
composed of an N-terminal PAS domain, followed by a 6TM 
arrangement and a C-terminal putative CNBD; B – Proposed 
arrangement of a tetrameric 6 TM K
+
 channel; C – Three 
subfamilies of EAG K
+
 channel family. Adapted from 
38
 and 
Heinemann, SH. 
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Sequence alignments show that members of the EAG family are closely related to cyclic 
nucleotide-gated cation channels as well as voltage-gated K+ channels 8. In particular, the 
human ERG potassium channel has great clinical importance since a set of inherited 
channel mutations give rise to long QT syndrome (LQTS), a condition characterized by 
arrhythmia, seizures and sudden death. However, the most common form of LQTS is 
acquired and is induced by drugs that block the channel, disrupting its normal function. 
EAG channels contain an N-terminal Per-Arnt-Sim (PAS) and a C-terminal putative 
cyclic nucleotide binding domain (CNBD) in addition to the characteristic six 
transmembrane helices (S1-S6) fold of voltage-gated K+ channels, fig. 1A. PAS and CNBD 
are cytosolic ligand binding domains and are thought to play important roles in these 
channels. However, their function is not fully understood nor have ligands been reported 
for either of these regulatory domains 9. 
Cyclic nucleotide binding domains (CNBDs) 
 Cyclic nucleotide binding domains regulate signaling pathways in both eukaryotes 
and prokaryotes.  These domains bind cAMP or cGMP and can be found in the bacterial 
catabolic activated protein (CAP, the first CNBD structure to be reported), or the 
eukaryotic nucleotide exchange factor 
(Epac), protein kinases (PKA, PKG) 10, 
and cyclic nucleotide-regulated 
channels (hyperpolarization-activated 
cyclic nucleotide-modulated channel – 
HCN 11 and cyclic nucleotide-gated 
channel - CNG).  
 Structurally, CNBDs are 
composed of an antiparallel β-roll of 
eight β-strands preceded by an α-helix 
(αA) and followed by α-helices αB 
(“hinge”) and αC (“lid”), fig. 2 and 
Fig. 2 - Wild-type structure of MlotiK CNBD with cAMP. 
Ligand is shown in stick model, β-roll and P-helix are in 
grey. PDB code 1VP6 
16
. 
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Appendix I for multiple sequence alignment of mEAG, hEAG, HERG, mHCN2 and MlotiK. In 
cyclic nucleotide-regulated channels, extra helices (fig. 2 and Appendix I) connect the 
channel pore to the CNBD and are responsible for transmitting the cAMP-induced 
conformation change to the pore; this region is known as the C-linker. An additional short 
α-helix, P-helix, is located between β-
strands 6 and 7 and is part of a key 
structural region - the phosphate binding 
cassette, PBC - that anchors the phosphate 
group of the cyclic nucleotide. There are 
several key residues involved in ligand 
coordination including the PBC’s glutamate, 
arginine and serine/threonine, fig. 3. The 
glutamate forms a hydrogen bond with the 
ribose, the serine/threonine interacts with 
the oxygens of the phosphate group of 
cAMP and the arginine forms a salt bridge 
with the phosphate, fig. 3 and Appendix I 11,12. Mutations on the PBC’s arginine in MlotiK 
13, mHCN2 14 and CNG decreased cyclic nucleotide binding affinity, but still allowed for 
cyclic nucleotide modulation in these channels. The lid region interacts with the base of 
the nucleotide through an arginine, tyrosine or tryptophan, fig. 3. Note that some 
domains adopt the CNBD fold without a canonical PBC and have gained the ability to bind 
other ligands, like the group heme in the case of CooA transcription activator 15. 
Fig. 3 - Close up of the residues of PBC (Glu298, 
Arg307, Ser308) and helix C that coordinate cAMP 
(Arg348) in MlotiK and. PDB code 1VP6 
16
. 
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 The CNBD of the bacterial channel 
MlotiK provides a good model for 
understanding the mechanism behind 
nucleotide activation since it was crystallized 
in the liganded (bound) and unliganded 
(unbound) states, fig. 4 12,16. The main 
difference between the bound and unbound 
states is the rearrangement of the helices 17. 
In the bound state, PBC and helix αC collapse 
around the ligand protecting it from the 
solvent while in the unbound state these 
can occupy multiple positions. Particularly 
important for channels is the repositioning 
of the loop between αA’ and αA since this movement is reflected on the position of αA’ 
(C-linker) and is thought to lead to changes in the gate. 
EAG channel inhibition by Ca2+/calmodulin 
Besides changes in the membrane electric field, EAG channels are also regulated 
by calmodulin. Elevation of intracellular calcium (Ca2+ half maximal inhibitory 
concentration, IC50, of ~100 nM 
18,19) inhibits channel activity. This means that EAG 
channels undergo inhibition just above basal cytosolic Ca2+ concentrations. It has been 
shown that this Ca2+ sensitivity requires the calcium-binding protein calmodulin (CaM) 
since neither Ca2+ nor CaM alone are able to block EAG currents 19. 
Three putative CaM binding regions were identified in a peptide array screen - one 
in the N-terminus (BD-N, between the PAS domain and S1) and two in the C-terminus 
(BD-C1 and BD-C2, just after the CNBD), fig. 5 20. Using fluorescence correlation 
spectroscopy and surface plasma resonance spectroscopy the following dissociation 
constants were estimated: 150-180 nM for BD-N and 130-200 nM for BD-C2. BD-C1 
showed low affinity (from 300 nM to >5000 nM) or no binding at all to hCaM, depending 
Fig. 4 - Superposition between liganded (PDB code 
1VP6, cAMP in stick model, β-roll in grey, α-helices 
in green) and unliganded structures of MlotiK CNBD 
(PDB code 1U12, β-roll in grey, α-helices in red). 
Large arrows indicate two positions of loop 
between αA’-αA. 
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on the assay and fluorescent label used 20. 
Although mutations in all three regions 
reduce the inhibition of EAG currents by Ca2+ 
19,20, channels with both disrupted BD-N and 
BD-C2 no longer bind Ca2+/CaM 21 which 
implies that BD-C1 is not able to bind CaM 
on its own but may do so in a cooperative 
manner. In general, mechanisms of 
regulation by CaM are not understood in 
many protein systems. In particular, the 
molecular mechanism behind EAG channel regulation by Ca2+/CaM remains unclear 
mainly due to the lack of structural information on the cytosolic binding domains in 
complex with CaM. 
Aims of the project 
 EAG channels are voltage-gated potassium channels that are inhibited by 
Ca2+/Calmodulin. These channels have a putative CNBD although they show no regulation 
by cyclic nucleotides nor bind these ligands. There are a lot of solved structures of CNBDs, 
including ones from a prokaryotic and eukaryotic cyclic nucleotide regulated channels, 
but there are none of the EAG potassium channel family. I wanted to solve a structure of 
an EAG CNBD to try to understand the structural features that make these domains not 
bind cyclic nucleotides. 
 Furthermore, I wanted to characterize the interaction of calmodulin with two 
putative calmodulin binding regions downstream of mEAG CNBD, determine the 
stoichiometry and see if a conformational change of the domain occurs upon binding of 
calmodulin. 
 
Fig. 5 - hEAG1 sequences identified as CaM binding 
sites. A - BD-N; B - BD-C1; C - BD-C2. Hydrophobic 
residues are in bold and basic residues in grey. 
Adapted from 
20
. 
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Materials and Methods 
Molecular biology 
 DNA constructs were produced using standard cloning techniques 22. Inserts were 
amplified by 25 cycles of PCR using the Pfu polymerase (Fermentas). Both PCR product 
and expression vector were digested with the two chosen restriction enzymes (Table 1) 
for 3h at 37 oC. Digestion products were purified by electrophoresis on a 1% agarose gel 
and the DNA bands with the expected molecular weight were excised under UV254 light. 
The DNA was extracted from the excised pieces of agarose using a QIAGEN Gel Extraction 
Kit. Ligation reactions were routinely performed using three different ratios of purified 
PCR product:expression vector in the presence of T4 DNA ligase (Fermentas) for 1h at 
room temperature. 
Table 1 - Description of the residue limits, oligonucleotides and restriction enzymes used to clone the 
constructs in the host vectors 
Host expression 
vector 
Residue limits of 
construct 
Restriction 
enzymes 
Oligonucleotides (5’3’) 
(F: forward; R: reverse) 
pRSFDuet-1 
(MCS1*/MCS2) 
(Novagen) 
kan
r
 
*thrombin cleavage site 
was added after BamHI 
to allow excision of His-
tag 
 
mEAG 503-724/- 
 
BamHI+NotI F-ccggatccgctggtgccgcgcggcagccagcagatg 
R-tacgccccctttaagcggccgcctactacttccgtttcatcc 
mEAG 552-724/- BamHI+NotI F-cccggatccgctggtgccgcgcggcagcacagagaaggtcctgc 
R-tacgccccctttaagcggccgcctactacttccgtttcatcc 
mEAG 552-724/hCaM 
full length 
 
BamHI+NotI/ 
NdeI+XhoI 
F-cccggatccgctggtgccgcgcggcagcacagagaaggtcctgc 
R-tacgccccctttaagcggccgcctactacttccgtttcatcc / 
F-gccatatggctgatcaactgacagaag 
R-gcgctcgagctacttcgctgtcatcatctgtac 
mEAG 552-757/hCaM 
full length 
 
BamHI+NotI/ 
NdeI+XhoI 
F-cccggatccgctggtgccgcgcggcagcacagagaaggtcctgc 
R-ccgctcgagctactaccctctctcggctgc / 
F-gccatatggctgatcaactgacagaag 
R-gcgctcgagctacttcgctgtcatcatctgtac 
pET-15b 
(Novagen) 
amp
r 
mEAG 552-707 
 
NdeI+XhoI F-cccggatccgctggtgccgcgcggcagcacagagaaggtcctgc 
R-ccgctcgagctactagaacacaatcctcttcctcag 
mEAG 562-707 
 
NdeI+XhoI F-ggaattccatatggacatgcgagccgac 
R-ccgctcgagctactagaacacaatcctcttcctcag 
mEAG 552-757 
 
NdeI+XhoI F-cccggatccgctggtgccgcgcggcagcacagagaaggtcctgc 
R-ccgctcgagctactagaacacaatcctcttcctcag 
12 
 
Note - after thrombin cleavage of the His-tag the protein fragment has the extra residues GS (pET-15b) or GSHM 
(pRSF      Duet-1). 
Ligations were transformed 22 into competent dH5α cells and plated onto LB agar 
plates with the appropriate antibiotic (50 mg/L kanamycin or 100 mg/L ampicillin). The 
following day colonies were picked and inoculated into LB liquid media+antibiotic. 
Cultures were grown overnight and positive clones were accessed by PCR with the 
respective forward and reverse oligonucleotides. DNA was prepared from these cultures 
using a miniprep kit and sequenced. 
Recombinant protein expression and purification - mEAG 
Protein expression followed a standard protocol: BL21(DE3) competent cells were 
transformed with expression vector and then plated on LB agar+antibiotic; the following 
day resuspended colonies were grown in liquid LB+antibiotic at 37 °C, 160 rpm until they 
reached an OD600 between 0.6-0.8. At that point cultures were put in an ice bath for 30 
min (induction of cold shock chaperones), after which ethanol was added slowly to a final 
concentration of 2% (induction of heat shock chaperones), and 0.5 mM IPTG was added 
for an overnight induction at 18 °C (12-16h). 
 Cultures were harvested by centrifugation at 5000 rpm, 20 min, 4 °C (Beckman 
rotor JLA 8-1000) and the resulting pellet was either stored at -20 °C or immediately 
resuspended in lysis buffer (table 2 for buffer description) supplemented with the 
protease inhibitors PMSF (1 mM), leupeptin (1 µg/mL) and pepstatin (1 µg/mL). Cell lysis 
was done in a cooled cell cracker (Emulsiflex-C5, AVESTIN) subjecting the lysate to three 
cycles at ~15000 psi. The lysate was then centrifuged at 20000 rpm (Beckman rotor JA-
25.50) for 45 min at 4 °C to remove cell debris. Purification was done in two steps, 
immobilized metal affinity chromatography (IMAC) followed by size-exclusion 
chromatography. Samples of each purification step were kept for SDS-PAGE analysis. In 
more detail, the supernatant from centrifugation was loaded onto TALON Cobalt beads 
(Clontech) pre-equilibrated with lysis buffer and three washes (W0+1+2) were made 
before eluting the His-tagged protein with elution buffer. 
13 
 
Table 2 - Buffers used during purification 
 Tris HCl pH 8.0 (mM) NaCl (mM) Imidazole (mM) DTT (mM) CaCl2
c 
(mM) 
Lysis buffer (W0) 50 
a
 150 0 0  
 
 
1 
5 
b
 
Wash buffer 1 (W1) 50 
a
 150 5 0 
300
 b
 0
 b
 
Wash buffer 2 (W2) 50 
a
 150 20 0 
Elution buffer (E) 50 
a
 150 150 0 
Gel filtration buffer 50 
a
 150 0 5 
a
 - 20 mM Tris HCl was used for crystallization trials. 
b
 - Buffers were used with constructs pET-15b mEAG552-757, pRSF Duet-1 mEAG 552-724/hCaM full length and pRSF 
Duet-1 mEAG 552-757/hCaM full length, in an attempt to increase purity. 
c
 - 1 mM CaCl2 was added when purifying mEAG co-expressed with hCaM. 
 
 Eluted protein, in the presence of thrombin to cleave the tag, was dialysed 
overnight at 4 °C against gel filtration buffer (volume ratio 1:~150) to remove excess 
imidazole using Spectra/Por membranes with molecular weight cutoff of 10000 Da. The 
dialysed non-tagged protein was concentrated in Vivaspin concentrators (Vivascience) 
with 10000 Da cutoff; the filtrate was passed through a 0.22 µm filter to remove particles. 
Further purification was achieved by 300-500 µL injections into a pre-equilibrated gel 
filtration Superdex 200 column (Pharmacia). 
 Protein purity was evaluated by SDS-PAGE (15% Laemli 22). Protein concentration 
was determined by measuring absorbance at 280 nm in an Ultrospec plus 
spectrophotometer (Pharmacia), using the calculated extinction coefficients obtained 
from ProtParam, a tool available at ExPaSy web server, 
http://www.expasy.org/tools/protparam.html (Table 3). 
Table 3 - Protein absorbances at 280 nm calculated by Protparam tool 
 OD280 (at 1 mg/mL) ε (M
-1
 cm
-1
) 
mEAG 503-724 0.880 22920 
mEAG 552-724 0.567 11460 
mEAG 562-707 0.691 11460 
mEAG 552-707 0.637 11460 
mEAG 552-757 0.443 11460 
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Recombinant protein expression and purification - hCaM 
BL21(DE3) competent cells were transformed with expression vector (pT7-7 
hCaM) and then plated on LB agar+ampicillin; the following day resuspended colonies 
were grown in liquid LB+ampicillin at 37 °C, 160 rpm until they reached an OD600 between 
0.6-0.8. 0.5 mM IPTG was added followed by a 3h induction at 37 °C. 
 Cultures were harvested by centrifugation at 5000 rpm, 20 min, 4 °C (Beckman 
rotor JLA 8-1000) and the resulting pellet was either stored at -20 °C or immediately 
resuspended in lysis buffer (table 4 for buffer description) supplemented with the 
protease inhibitors PMSF (1 mM), leupeptin (1 µg/mL) and pepstatin (1 µg/mL). Cell lysis 
was done in a cooled cell cracker (Emulsiflex-C5, AVESTIN) subjecting the lysate to 3 
cycles at ~15000 psi. The lysate was then centrifuged at 20000 rpm (Beckman rotor JA-
25.50) for 45 min at 4 °C to remove cell debris. Supernatant was loaded onto a Phenyl 
Sepharose CL-4B (Sigma-Aldrich) column equilibrated in EDTA buffer to absorb proteins 
that bind in a calcium-independent manner. The flow-through that contains CaM was 
collected and CaCl2 was added to a final concentration of 5 mM. The calcium 
supplemented flow-through was loaded onto another phenyl sepharose column 
equilibrated in calcium buffer. This second step allows CaM to interact with the phenyl 
sepharose matrix since there is calcium available. Washes were made with calcium buffer 
+ NaCl and calcium buffer. Calmodulin was eluted with EDTA buffer. Protein purity was 
evaluated by SDS-PAGE and concentration was determined by measuring absorbance at 
277 nm (calmodulin does not have any tryptophans in the sequence) in an Ultrospec plus 
spectrophotometer (Pharmacia), using the extinction coefficient ε277=3029 M
-1 cm-1 23. 
Calmodulin was dialyzed against storage buffer using a dialysis membrane with 3500 Da 
cutoff and stored at -80 °C. 
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Table 4 - Buffers used for CaM purification 
 Tris HCl pH 7.5 
(mM) 
NaCl 
(mM) 
EDTA 
(mM) 
DTT 
(mM) 
CaCl2 
(mM) 
NaN3 
(mM) 
Lysis buffer (EDTA 
buffer + NaCl) 
50 100 2 5 0 
 
0 
EDTA buffer 50 0 2 5 0 0 
Calcium buffer 50 0 0 5 1 0 
Calcium buffer + 
NaCl 
50 100 0 5 1 0 
Storage buffer 2 0 0 2 0 1 
 
Crystallography 
 Crystallization trials were performed using the vapour diffusion method 24. Pure 
protein was concentrated up to 10 mg/mL in 20 mM Tris HCl pH 8, 150 mM NaCl, 5 mM 
DTT and centrifuged at 14000 rpm for 30 min in a refrigerated table-top centrifuge to 
remove particles before setting plates. 
 The following commercial random crystallization screens were used: Nextal Tubes 
Classics Suite, Nextal Tubes Classics II Suite, Nextal Tubes Classics L Suite, MBClass Suite 
(QIAGEN); Wizard I+II, Precipitant Synergy P64 (Emerald Biosystems); Crystal Screen I+II, 
MembFac (Hampton Research). 96-well sitting drop plates were set at 4 and 20 °C using a 
drop with 1 µL:1 µL mixture of precipitant solution to protein solution and 100 µL of 
commercial solution in the reservoir. When crystals showed up, fine screens around the 
hit condition were prepared by varying pH, precipitant concentration, ionic strength and 
ratio between precipitant solution and protein solution and set in 24-well plates with 300 
µL of precipitant solution in the reservoir. 
Microseeding was necessary to reproduce some crystals 25,26. A crystal was picked, 
washed and diluted in a solution with higher precipitant concentration and then crushed 
into very small pieces. With the help of a 0.05 mm cryoloop, several micro crystals were 
transferred into freshly set drops. Volume ratios of protein:precipitant of 3:1, 2:1 and 1:1 
were also tried to further optimize crystal growth. 
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Cryoprotectant solutions were prepared by supplementing the crystallization 
solution with cryoprotectant agent - PEG 400 or glycerol - generally in 5% steps 27,28. The 
solutions that showed vitrification in the crystal loop when exposed to a stream of N2 
vapour at 100 K were selected. Crystals were prepared for data collection by fast 
equilibration in several intermediate solutions, ending in the final cryoprotectant solution 
and flash frozen in liquid nitrogen.  
Data collection and refinement 
A complete dataset was collected at the ID14-4 beamline of the European 
Synchrotron Radiation Facility (ESRF). Data were integrated using the program Mosflm 
and scaled using SCALA, both from Collaborative Computational Project 4 (CCP4) 29. Initial 
phases were calculated by molecular replacement using Phaser (CCP4). Model refinement 
was done in Refmac5 (CCP4) and in the final stages of refinements Phenix 30 was used, 
together with TLS parameters 31. Model building was performed in Coot 32 and figures 
were made using Pymol 1.2r2 (www.pymol.org). 
Controlled and in situ proteolysis for protein crystallization 
 Pre-screenings to identify ideal proteases were performed with four proteases - 
trypsin (Worthington Biochemical Corporation), chymotrypsin (Worthington Biochemical 
Corporation), Lys-C (Roche) and Glu-C (Roche). Stock solutions of protease were serially 
diluted into a buffer comprising 10 mM HEPES pH 7.5 and 500 mM NaCl 33,34. 15 µg of 
protein, in gel filtration buffer, were digested with each protease for 1h at room 
temperature using the following mass ratios of protease:protein - 1:50, 1:100, 1:500, 
1:1000.  Digestions were interrupted by addition of SDS sample buffer (62.5 mM Tris HCl 
pH 6.8; 25% glycerol; 2% SDS; 0.01% Bromophenol Blue; 0.7 M β-mercaptoethanol). 
Samples were analysed by SDS-PAGE. Proteases and ratios who gave rise to the larger 
cleavage products were further optimized by varying times of incubation from 45 min to 
1h15min. These reactions were stopped with 0.1% formic acid and sent for mass 
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spectrometry analysis with 4700 MALDI TOF/TOF Proteomics Analyzer (Applied 
Biosystems) for identification of fragment masses. 
 The best conditions (combination of protease and reaction time) were also used 
for in situ proteolysis. Two strategies were applied: 1) protease at the chosen ratio was 
mixed with the protein for 1h at room temperature. Reaction was then stopped with an 
appropriate protease inhibitor and crystallization plates were set. 2) protease was added 
to the protein on ice just before setting plates. The reaction was not stopped 33,34. 
Cross-linking between mEAG 552-757 and CaM 
 Molar ratios of 1:2, 1:5, 1:10 of mEAG 552-757 (2 µM) and CaM were incubated in 
20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA in the presence and absence of 5 mM 
CaCl2 for 30 min at room temperature. Stock solutions of bifunctional primary amine 
cross-linkers (EGS spacer arm: 16 Å and DTSSP spacer arm: 12 Å) were prepared in 100% 
DMSO or in 5 mM citrate pH 5.5, respectively. Cross-linker was added to a final 
concentration between 0.5-2 mM and the reaction took place for 1 h at room 
temperature after which it was stopped by addition 50 mM Tris HCl pH 8 (final 
concentration). Samples were precipitated with tricloroacetic acid (TCA): Ice cold TCA 
100% was added to the samples to a final concentration of 16.6%. Samples were 
incubated on ice for 30 min followed by a 30 min centrifugation at top speed in a 
refrigerated table-top centrifuge. The supernatant was carefully removed and dry 
acetone was added to the pellet followed by 15 min incubation in ice. The samples were 
centrifuged at top speed, 4 °C, the supernatant was removed and the pellets were air 
dried before adding sample buffer and analyzing by SDS-PAGE. 
Derivatization of calmodulin with the fluorophore Dansyl-Cl 
 Wild-type hCaM was derivatized with 5-(dimethylamino)naphthalene-1-sulfonyl 
chloride (Dansyl-Cl, Molecular Probes), a reagent that reacts with primary amines, as 
described in 35,36. Briefly, CaM was diluted to 1 mg/mL in 20 mM sodium bicarbonate pH 
10, 100 mM NaCl, 250 µM CaCl2. Dansyl-Cl was diluted to 1 mg/mL in dry acetone and 1.5 
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moles dansyl-Cl were added per mol of CaM. The reaction took place in the dark, at room 
temperature, for 60-90 min after which it was stopped with 50 mM Tris HCl pH 8. Excess 
dye was removed using a size exclusion Sephadex G25 column (Pharmacia) and buffer 
was exchanged to 20 mM Tris HCl pH 8, 150 mM NaCl. Dansyl-CaM was kept at 4 °C in the 
dark. The amount of dansyl incorporated was estimated by determination of absorbance 
at 334 nm (λmax bound dansyl, ε334=3400 cm
-1 M-1) and related to protein concentration to 
give moles dansyl/mol CaM.  
Fluorescence assay - binding of Dansyl-CaM to mEAG 552-757 
 Dansyl-CaM at 40 nM was incubated with different concentrations of protein at 
room temperature, for at least 20 min, in 50 mM Tris HCl pH 8, 150 mM NaCl, 5 mM 
MgCl2, 0.1 mM EGTA and 2 mM CaCl2 (1.9 mM free Ca
2+). Fluorescent measurements 
were made at 26 °C using a Horiba Fluoromax-4 spectrofluorimeter. All emission spectra 
were obtained using an excitation wavelength of 340 nm, with slit widths of 6 nm 36. 
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Results and Discussion 
Calibration of Superdex 200 column 
 To be able to translate size-exclusion column elution volumes (Ve) into 
approximate molecular weights, the Superdex 200 column used for purification of all 
protein constructs was calibrated using a protein standard kit (Sigma) The standards used 
were blue dextran (MW=2000 kDa, corresponding to the void volume of the column, V0), 
apoferritin (MW=443 kDa), β-amylase (MW=200 kDa), ADH (MW=150 kDa), BSA (MW=66 
kDa) and myoglobin (MW=16.7 kDa). The log MW was ploted against Kav (Kav=
     
     
 in 
which Vt is the total bed volume 24 mL) and a line was fitted to the points, fig. 6. 
  
Fig. 6 - Calibration curve of Superdex 200 size-exclusion column 
mEAG 503-724 
The first construct tested - mEAG 503-724 - included the complete C-linker, αA’-
αF’, and extended about 20 residues after the CNBD, after BD-C1 (see Appendix 1). This 
protein was very sensitive to proteolysis; the protein also precipitated heavily during 
elution from the His-tag affinity beads and did not have a monodisperse size-exclusion 
profile. For all the problems cited above mEAG 503-724 was abandoned. 
Kav = -0,2702 log MW + 0,8823
R² = 0,9904
0
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mEAG 552-724 
  mEAG 552-724 starts at the 
beginning of helix αC’ of the C-linker and 
results in a protein with a molecular 
weight of 19926 Da after excision of the 
His-tag. This truncation is soluble and 
gives a yield of 10-20 mg pure protein/L 
of culture. In size-exclusion 
chromatography it is eluted as a species 
of 20 kDa which is very close to the actual 
molecular weight of the protein, fig. 7. 
Extensive random crystallization 
screening of mEAG 552-724 did not result 
in any hits.  
 
 
 
Controlled proteolysis / In situ proteolysis 
mEAG 552-724 was then used in controlled proteolysis trials. This technique is 
useful for defining a protein core that is partially resistant to proteases, and which will 
potentially crystallize more easily and yield better diffracting crystals 33,34. 
Of the four proteases originally tested, trypsin produced fragments that were too 
small and Glu-C hardly cleaved the protein at all, even at high concentrations, fig. 8 and 9. 
Digestions with chymotrypsin at 1:500 and Lys-C at 1:100 (protease:protein mass ratio) 
originated species with a molecular weight corresponding to removal of small portions of 
the protein termini; these conditions were further optimized by varying time of digestion 
(fig. 10). The proteolysis products of the chymotrypsin and Glu-C after 1h digestion were 
Fig. 7 - Gel filtration profile and SDS-PAGE analysis of 
mEAG 552-724. MW - molecular weight markers; + 
tag - protein before thrombin cleavage; vv- void 
volume; 1-4 - fractions of the peak. Arrow indicates 
the sample injection. Chart speed 0.5 cm/mL. The 
molecular weight markers are the same for all the 
gels. 
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sent for mass determination of the fragments by mass spectrometry. Data analysis was 
performed using the software Paws (Genomic Solutions Inc.). The chymotrypsin (1:500) 
digestion gave rise to a species of 17726.9 Da corresponding most likely to mEAG 552-707 
and the Lys-C (1:100) digestion originated a species of 16728.2 Da that corresponds to 
mEAG 562-709, see spectra in Appendix IV. The residues Thr552, Asp562 and Phe707 
correspond to the beginning of the helix αC’, helix αD’ and a few residues after the end of 
helix αC, respectively (see MSA, Appendix I). 
In situ proteolysis consists of the addition of trace amounts of protease to 
crystallization trials without stopping the reaction. This has proven to be a successful 
Fig. 8 - SDS-PAGE analysis of trypsin (T) and 
chymotrypsin (C) digestion products (1 h at room 
temperature). Ct - control undigested protein; 1 - T 
1:50; 2 - T 1:100; 3 - T 1:500; 4 - T 1:1000; 5 - C 1:50; 6 - 
C 1:100; 7 - C 1:500; 8 - C 1:1000 
Fig. 10 - SDS-PAGE analysis of chymotrypsin (C) 
1:500 and Lys-C (L)  1:100 digestion products (at 
room temperature). Ct - control undigested protein; 
1 - C 45min; 2 - C 1h; 3 - C 1h15; 4 - L 45min; 5 - L 1h; 
6 - L 1h15 
MW   Ct    1         2        3        4                5        6         7        8 
         Trypsin  Chymotrypsin 
Ct  MW   1        2        3        4                5        6         7        8 
         Glu-C         Lys-C 
Fig. 9 - SDS-PAGE analysis of Glu-C (G) and Lys-C (L) 
digestion products (1 h at room temperature). Ct - 
control undigested protein; 1 - G 1:50; 2 - G 1:100; 3 - 
G 1:500; 4 - G 1:1000; 5 - L 1:50; 6 - L 1:100; 7 - L 
1:500; 8 - L 1:1000 
MW   Ct       1            2           3                     4          5            6          
         Chymotrypsin              Lys-C 
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crystallization technique for proteins that had previously failed in crystallization trials and 
structure determination 33,34. In situ proteolysis crystallization trials of mEAG 552-724 in 
the presence of chymotrypsin 1:500 or Lys-C 1:100 did not yield any hits. 
mEAG 562-707 
Based on the controlled proteolysis results two new constructs were designed: 
mEAG 562-707 and 552-707. After expression and purification of both protein fragments 
crystallization trials were performed. During purification of mEAG 562-707, precipitation 
was detected in the dialysis and concentration steps. The size-exclusion profile was 
monodisperse, did not have a significant amount of aggregated protein, and the protein 
migrated as a species of approximately 14 kDa (fig. 11). 
Random screen crystallization plates were set and needle-looking crystals were 
obtained with Nextal Classics II condition 57: 0.05 M ammonium sulphate, 0.05 M bis-tris 
HCl pH 6.5 and 30% (v/v) pentaerythritol ethoxylate (15/4 EO/OH) at 4 °C, fig. 12. Fine 
screens around that condition were prepared but crystals were never obtained. 
Fig. 11 - Gel filtration profile and SDS-PAGE 
analysis of mEAG 562-707. MW - molecular 
weight markers; + tag - protein before thrombin 
cleavage; P - centre of peak. Arrow indicates the 
sample injection. Chart speed 0.5 cm/mL. 
 + tag   MW      P 
Fig. 12 - Needle-like crystals of mEAG 562-707 at 12 
mg/mL in 0.05 M ammonium sulphate, 0.05 M bis-tris 
HCl pH 6.5 and 30% (v/v) pentaerythritol ethoxylate 
(15/4 EO/OH) at 4 °C. 
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Subsequent protein preparations showed intense precipitation. For all this, it was decided 
not to pursue this protein any further. 
mEAG 552-707 
 In contrast to the smaller construct, 
mEAG 552-707 did not precipitate. The 
expected molecular weight of the protein is 
17995 Da and it migrated in size-exclusion as a 
16 kDa species fig. 13.  Random crystallization 
screens resulted in a hit.  Condition 97 of 
Nextal Classics II - 0.2 M tri-sodium citrate 
dihydrate, 20% PEG 3350 - showed a single 
cluster of well defined crystals and multiple 
spherolites at 4 °C (fig. 14). Fine screens 
around the condition did not reproduce the 
crystals of mEAG 552-707. However, 
microseeding proved to be the solution for 
obtaining new crystals, fig. 15. The 
concentration of precipitant was lowered to the range of 8-18% PEG 3350 in order to 
MW  +tag     P 
Fig. 14 - Crystals of mEAG 552-707 12 mg/mL in 
0.2 M tri-sodium citrate dihydrate, 20% PEG 
3350 at 4 °C are indicated by an arrow. 
Fig. 13 - Gel filtration profile and SDS-PAGE 
analysis of mEAG 552-707. MW - molecular 
weight markers; + tag - protein before thrombin 
cleavage; P - centre of peak. Arrow indicates the 
sample injection. Chart speed 0.5 cm/mL. 
Fig. 15 - Crystals of mEAG 552-707 obtained by 
microseeding. 
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improve the quality of the crystals, otherwise they grew too fast and formed small and 
imperfect clusters. The crystals were flash-frozen on a cryoprotectant solution containing 
25% PEG 3350, 0.2 M tri-sodium citrate and 10% glycerol.  
Data collection 
 Two data sets were collected at 100 K from a single crystal of mEAG 552-707, 
comprising 270 images, 1° oscillation each, with a crystal-to-detector distance of 290 mm. 
To record the high-angle diffraction spots (at 2.2 Å, high resolution) the first data set was 
collected with a beam transmission of 100%. For the low-angle diffraction spots (low 
resolution), that were overloaded on the previous data set, another data set was 
collected with an attenuated beam (transmission of 10%). 
 From each data set, 90 images were indexed in space group P3121 and integrated 
using Mosflm. Only 90 images were used because the crystal suffered radiation damage 
during data collection and lost diffraction quality. Mosflm suggested the spatial group 
(Table 4), but since this group has the same reflection conditions as P3221 (000l:l=3n), it 
was only determined at a later stage. The integrated data (high and low resolution) were 
merged into one full data set and the statistics are shown on table 5. 
Table 5 - mEAG 552-707 crystal data. 
Crystal data  
      Crystal system Hexagonal 
      Space group P3121 
      Unit cell parameters 
            a=b (Å) 
            c (Å) 
            α=β (°) 
            γ (°) 
 
60.3 
85.4 
90 
120 
Data-collection details  
      Diffraction source ESRF beamline ID14_4 
      Wavelenght (Å) 0.9765 
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      Detector ADSC Quantum Q315r 
      Resolution range (Å) 52.3-2.2 (2.31-2.2) 
      No unique reflections 9566 (1356) 
      No measured reflections 39240 (17118) 
      Multiplicity 6.2 (5.2) 
      Completeness (%) 99.4 (97.5) 
      I/σI 4.8 (2.2) 
      Rsym (%) 8.9 (25.1) 
Note - the values in parenthesis correspond to statistics of the highest resolution shell of data 
 The cell content analysis tool of CCP4 proposed one molecule per unit cell and 
50% solvent. Molecular replacement was attempted with Phaser, using mHCN2 CNBD 
structure (PDB code 1Q3E) as a search model (23% identity with mEAG 552-707) but it 
failed. The next step was to submit mEAG 552-707 sequence to the protein structure 
prediction server Phyre 37. The output that comes from this server is a set of ten models 
(.pdb files) based on the highest scoring alignments. From the top ten models, an 
ensemble of six search models was used in Phaser - models of mEAG 552-707 created 
from PDB codes 1Q3E, 1VP6, 2PTM, 1CX4, 1NE6 and 2PQQ. This strategy provided a well 
defined solution. The electron density maps calculated with this solution showed features 
that were not present in the search models, confirming the validity of the solution. 
Model building and refinement 
Model building was performed in Coot 32.  Refinement of the structure was made 
using the programs Refmac5 (CCP4) and Phenix 30; TLS refinement 
(translation/libration/screw axis) 31 was applied to further lower Rfree and Rwork by dividing 
the model into ten groups as determined by the server 
(http://skuld.bmsc.washington.edu/~tlsmd). The model is currently in the final stages of 
refinement and validation with an Rfree=22.6% and Rwork=19.4%. 
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Analysis of structure 
The structure of mEAG 552-707 shows a canonical CNBD fold consisting of helix αA 
followed by an antiparallel β-roll and two helices, αB and αC, fig. 16. αC is relatively short, 
only has two helical turns, and is followed by a 14-residue coil C-terminal region that lies 
on the surface of the β-roll. There are also three short helices at the N-terminus (fig. 16, 
αD’, αE’, αF’); these helices are part of the C-linker that connects the domain to the pore. 
There is no electron density for the first 14 residues of the protein. 
Fig. 16 - Two orientations of the mEAG 552-707 structure. CNBD helices are colored in blue, β-roll in grey 
and C-linker helices (αD’, αE’ and αF’) in cyano. 
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One of the reasons to solve this structure was to understand why this domain 
does not bind cyclic nucleotides. No electron density corresponding to a cyclic nucleotide 
molecule could be identified in the ligand binding pocket of mEAG. Comparison of the 
binding pockets of the MlotiK liganded and unliganded structures with the equivalent 
region in the mEAG 552-707 structure shows that the residues close to the nucleotide 
base are unchanged (Val, Phe - fig. 17 in stick model); in contrast residues that in the 
MlotiK structure interact with the ribose and phosphate groups of the nucleotide are very 
different in the mEAG structure. 
Fig. 17 - Close up of the nucleotide binding pocket in MlotiK liganded structure (1VP6 in green), in MlotiK 
unliganded structure (1U12 in red) and equivalent region in mEAG 552-707 (in blue). Residues of the PBC are 
labelled. 
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For instance, phosphate binding cassette (PBC) residues that are known to 
coordinate the ligand (Glu298, Arg307 and Ser308 in MlotiK - fig. 17 in sticks and labelled) 
are substituted in mEAG by residues with shorter side chains - Asp646, Ser667 and 
Cys668, respectively. Furthermore, the loop between β6 and β7 in mEAG has two extra 
residues relative to MlotiK and mHCN2, and it adopts a different conformation. This is 
particularly evident in the different position of the negatively charged residue of the PBC 
(Glu298 in MlotiK and Asp646 in mEAG). Overall the pocket of mEAG is wider than in 
either one of MlotiK structures (fig. 17); distances between the α-carbons of PBC’s (Phe, 
Gly) and the residue across (Cys, in mEAG) are 2 Å larger than in the bound and unbound 
structures. There are four residues in the loop β6- β7 whose side chains were disordered 
and showed no electron density so they were mutated to Ala in the final model: 
Lys650Ala, Glu651Ala, Leu654Ala and Gln656Ala. 
The mEAG domain structure was superposed with the two structures of MlotiK 
through the β-roll, a region that hardly varies among bound and unbound strutures (fig. 
18). It has been demonstrated that the major change between liganded and unliganded 
states of CNBDs is the relative position of the helices. The position of the helices in mEAG 
structure is much more similar to the bound state of MlotiK, fig. 18. First of all, the αC-
helix in mEAG aligns with the αC-helix of MlotiK bound state. Moreover, the region 
Fig. 18 - Superposition of mEAG (blue), liganded (1VP6, green) and unliganded (1U12, red) structures of 
MlotiK. β-rolls are represented in ribbon, cAMP of 1VP6 is in stick model. 
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formed by C-linker/loop/αA-helix in the mEAG structure basically occupies the same 
position on the surface of the β-roll as in the bound structure of MlotiK. Therefore, 
although there is no cyclic nucleotide in the ligand binding pocket of mEAG, it appears 
that it has adopted a bound state conformation. Strikingly, the C-terminal coil region that 
follows the αC-helix actually enters the binding pocket (fig.19); and the side chains of 
residues Tyr699 and Leu701 occupy the volume of the cAMP molecule in the bound 
structure of MlotiK (fig. 19, zoom in). The tyrosine ring lies on the same volume occupied 
by the nucleotide base and the leucine is positioned on the phosphoribose site.  
These residues are fairly conserved among EAG channels, the tyrosine (consensus 
of 46%) can be a phenylalanine (40%) or cysteine (14%) while the leucine (consensus of 
96%) is sometimes substituted by isoleucine (4%). The observation of a bound state 
conformation, together with the positioning of Tyr699 and Leu701 in the binding pocket 
raises the possibility that, in the mEAG channel, the region immediately after the αC-helix 
may function as an internal ligand. 
Immediately downstream from these residues there is a putative calmodulin 
binding site (BD-C1), fig. 19 and Appendix 1. This suggests a possible mechanism whereby 
Fig. 19 - Surface view of the β-roll with C-terminal coil entering the pocket and zoom in on the residues (in 
sticks) that occupy the same space as cAMP (in lines), from MlotiK bound structure 1VP6. 
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calmodulin modulates the switch between bound and unbound conformations of the 
CNBD and ultimately regulates the channel. Calmodulin binding to BD-C1 would shift the 
equilibrium between the bound and unbound conformations of the domain by stabilizing 
the conformation where the internal ligand is out of the pocket. This release of the 
internal ligand would induce a conformational change that is transmitted via C-linker to 
the pore, shutting it closed. 
mEAG 552-724/ hCaM and mEAG 552-757 / hCaM - co-expression 
The hypothesis raised above for calmodulin regulation lead us to propose four 
possible models for calmodulin binding. These models take in consideration that there 
are two putative calmodulin-binding sites after the domain, less than 30 residues apart 
from each other (fig. 20): 
1) BD-C1 and BD-C2 bind CaM independently, one molecule in each site; 
2) one CaM molecule wraps both CaM binding sites; 
3) the two sites show cooperativity (CaM binding to one of the sites will 
change the affinity for the second); 
4) BD-C1 was misidentified in the peptide screen and CaM only binds BD-
C2.  
 
Fig. 20 - Scheme of the four proposed models for calmodulin binding. 1) two independent binding sites; 2) 
one CaM binds both sites; 3) there is cooperativity between both sites; 4) there is only one site (BD-C2). 
Calmodulin is represented in orange. 
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The models proposed above were tested by first checking if calmodulin binding 
depends on BD-C1. With that in mind two new constructs were designed and cloned into 
MCS1 of co-expression vector pRSF-Duet1: mEAG 552-724 only includes BD-C1; mEAG 
552-757 contains both BD-C1 and BD-C2 and are His-tagged. On the MCS2 these 
constructs also encode and express untagged hCaM.  
IMAC purification of mEAG 552-724 did not pull any calmodulin. Assembly of a 
complex between mEAG 552-724 and purified CaM was not detected by native gel 
analysis. These results are in accordance with published data that state that BD-C1 has 
low affinity to CaM and might not be able to bind CaM without BD-C2 20,21. 
Purification of mEAG 552-757 co-expressed with hCaM resulted in pulling down a 
complex between the two proteins, when the IMAC was performed in the presence of 
CaCl2. The mEAG 552-757/CaM complex migrated in gel filtration as a 72 kDa species (fig. 
21), considerably higher than mEAG 552-757 (~31 kDa species) or CaM (~25 kDa species) 
alone (fig. 23) and may correspond to an oligomeric form of mEAG 552-757/CaM. 
To evaluate the complex and determine its stoichiometry it was necessary to 
prepare mEAG 552-757 without CaM. Since this protein expressed alone experienced 
severe proteolysis, a protocol had to be developed to separate mEAG 552-757 from CaM 
through a step of anion exchange chromatography in the presence of EDTA. The 
calculated isoelectric point (pI) of mEAG 552-757 and CaM are 8.9 and 4, respectively. 
Because of this difference in pI, these two proteins are easily separated in an anion 
exchange matrix at neutral pH. 
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Fig. 21 - Gel filtration profile and SDS-PAGE analysis of mEAG 552-757. MW - molecular weight markers; P - 
centre of peak. Arrow indicates the sample injection. Chart speed 1 cm/mL. 
Three approaches were used to begin the characterization of the complex 
between CaM and mEAG 552-757: gel filtration, cross-linking and a fluorescence binding 
assay. 
Gel filtration profiles of the complex  and chemical cross-linking 
mEAG and CaM were incubated at ratio of 1:1 for 30 min on ice, in the presence of 
calcium, and analysed in a size exclusion column Superdex 200. A single peak of 
approximate molecular weight 72 kDa was observed, demonstrating that it is possible to 
reconstitute the complex formed in the bacteria (fig. 22). Formation of a complex in the 
mEAG 
CaM 
               P       MW 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
O
D
 2
8
0
Elution volume/mL
mEAG
CaM
mEAG + CaM 1:1
Fig. 22 - Superposition of gel filtration profiles of mEAG 552-757, CaM and 1:1 molar ratio of mEAG:CaM. 
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presence of a higher ratio of CaM (1:2), did not alter the migration of the 72 kDa species 
and showed the emergence of a peak at the elution volume of CaM (data not shown), 
hinting that CaM was in excess.  
Chemical cross-linking of proteins allows the capture of transient interactions 
between proteins that might otherwise be hard to detect.  Incubation of mEAG 552-757 
with different molar ratios of CaM in the presence of cross-linking agents originated a 
single species, in a Ca2+-dependent manner, with a molecular weight between 37 and 50 
kDa, fig. 23. This species most probably corresponds to a 1:1 complex between CaM and 
mEAG 552-757 of expected molecular weight 43 kDa. Overall, the gel filtration and cross-
linking experiments suggest that the complex between CaM and mEAG 552-757 involves 
one molecule of each protein. 
Fluorescent assay with dansyl-CaM 
Previous reports of binding affinities of CaM to EAG calmodulin-binding sites have 
made use of small peptides 20. To better understand the interaction between CaM and 
the mEAG C-terminal domain a fluorescence assay with dansyl-CaM was performed. 
Dansyl-Cl is an environmental sensitive fluorophore. Dansyl-modified CaM retains 
the physical and biochemical properties of native CaM and has been used to monitor the 
formation of Ca2+-dependent complexes with several calmodulin-binding proteins 36. Apo 
dansyl-CaM (without calcium) shows an emission maximum at 520-525 nm. Upon 
Fig. 23 - SDS-PAGE of cross-linking products. Controls are on the left and mixtures of mEAG and CaM on the 
right. 
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addition of Ca2+ the maximum shifts to ~505 nm and there is an increase in fluorescence 
intensity (data not shown). This Ca2+-dependent blue shift results from a major 
conformational change that increases the hydrophobicity of the environment of the 
dansyl group increasing its quantum yield 36. This blue shift and fluorescence intensity 
increase is further accentuated in the presence of a calmodulin ligand 36. 
To assess if this assay could be applied to our protein system a test was 
performed, fig. 24. Three mixtures of dansyl-CaM and mEAG 552-757 were prepared 
either in the absence of Ca2+ (red); with 2 mM CaCl2 (green) or with 2 mM CaCl2 and 4 mM 
EGTA (blue) and fluorescence emission spectra were recorded. In the presence of Ca2+ 
there is an increase in fluorescence signal as well as a shift in the emission maximum from 
514 nm to 483 nm that is almost completely reverted when excess EGTA is present. This 
result shows that the dansyl-CaM assay reports the formation of a Ca2+-dependent 
complex between mEAG 552-757 and CaM. 
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Fig. 24 - Emission spectra of 40 nM dansyl-CaM + 1 µM mEAG 552-757 with: no calcium (red); 2 mM CaCl2 
(green) and 2 mM CaCl2 + 4 mM EGTA (blue). 
Using this assay, a titration experiment was performed. Mixtures of 40 nM dansyl-
CaM and increasing amounts of mEAG 552-757 were prepared and emission spectra were 
recorded. A progressive increase in fluorescence intensity, together with a blue shift of 
the emission maximum were observed with increasing mEAG 552-757, fig. 25, consistent 
with binding of mEAG to dansyl-CaM. The fluorescence intensities at this wavelength 
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Fig. 26 - Data fitting to a hyperbolic function of four titration 
experiments. 
 
were normalized using the formula        
    
       
 in which F norm is proportional to 
the concentration of [mEAG-Cam] complex. Averages and standard deviations of four 
titration experiments were calculated and plotted using OriginPro8. 
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Fig. 25 - Emission spectra of 40 nM dansyl-CaM and increasing amounts of mEAG 552-757. 
The normalized data were fitted to single-site binding model using the following 
hyperbolic function 
F     
              
                 
  The 
determined Kd was 163 ± 18 
nM (N=4), fig. 26, which 
compares very well to the 
previously determined 
affinity between CaM and 
the BD-C2 peptide 20. 
Overall, these results suggest 
that only one molecule of 
calmodulin binds mEAG 552-
757 and so far I have not been able to prove that BD-C1 is involved in CaM binding. 
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Conclusions 
 A crystal structure of a putative CNBD from the EAG channel family was 
determined at a 2.2 Å resolution. The structure has the characteristic fold of cyclic 
nucleotide binding domains, and it appears to adopt a conformation that is equivalent to 
the bound state observed in CNBDs. Comparison between the binding pockets of CNBDs 
and the equivalent region in mEAG C-terminal domain show several important 
differences, consistent with the inability of mEAG to bind cyclic nucleotides. 
 The mEAG 552-707 structure shows a very interesting feature: two conserved 
residues in EAG channels reside in the volume occupied by the cAMP molecule in CNBD 
structures. Moreover, immediately after these residues there is a putative calmodulin 
binding site (BD-C1). These observations together with the bound state conformation of 
the mEAG domain structure have lead to the following hypothesis: a sequence of the C-
terminal domain of the EAG channel acts as an internal ligand. Binding of CaM shifts the 
equilibrium towards a conformation this internal ligand is released from the binding 
pocket. This conformational change is transmitted to the pore region inhibiting the 
channel. 
Future work 
The hypothesis raised above requires further testing. For example, the importance 
of the internal ligand residues might be assessed by the functional impact of point-
mutations in electrophysiological recordings in the presence and absence of Ca2+-
calmodulin. 
Introduction of point-mutations in the different CaM binding sites, together with 
biochemical and structural analysis will provide a better picture of CaM binding and 
regulation. 
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Appendix I - Multiple sequence alignment of full-length mEAG (NP_034730.1), hEAG 
(NP_758872.1), hERG (NP_000229.1), mHCN2 (NP_032252.1) and MlotiK (Q98GN8.1) 
 
mEAG            MTMAGGRRGLVAPQNTFLENIVRRSNDTN--FVLGNAQIVDWPIVYSNDGFCKLSGYHRA 58 
hEAG            MTMAGGRRGLVAPQNTFLENIVRRSNDTN--FVLGNAQIVDWPIVYSNDGFCKLSGYHRA 58 
HERG            ---MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCELCGYSRA 57 
mHCN2           ---MDARGGGGRPGDSPGTTPAPGPPPPP---PPPAPPQPQPPPAPPPNPTTPSHPESAD 54 
MlotiK          ------------------------------------------------------------ 
                                                                             
          PAS DOMAIN 
mEAG            EVMQKSSACSFMYGELTDKDTVEKVRQTFENYEMNSFEILMYKKNRTPVWFFVKIAPIRN 118 
hEAG            EVMQKSSTCSFMYGELTDKDTIEKVRQTFENYEMNSFEILMYKKNRTPVWFFVKIAPIRN 118 
HERG            EVMQRPCTCDFLHGPRTQRRAAAQIAQALLGAEERKVEIAFYRKDGSCFLCLVDVVPVKN 117 
mHCN2           EPGPRARLCSRDSACTPGAAKGGANGECGRGEPQCSPEGPARGPKVSFSCRGAASGPSAA 114 
MlotiK          ------------------------------------------------------------                                                                    
 
mEAG            EQDKVVLFLCTFSDITAFKQP--------------------------------------- 139 
hEAG            EQDKVVLFLCTFSDITAFKQP--------------------------------------- 139 
HERG            EDGAVIMFILNFEVVMEKDMVGSPAHDTNHRGPPTSWLAPGRAKTFRLKLPALLALTARE 177 
mHCN2           EEAG-------------------------------------------------------- 118 
MlotiK          ------------------------------------------------------------                                         
 
mEAG            ---------------------------------------IEDDSCKGWG----------- 149 
hEAG            ---------------------------------------IEDDSCKGWG----------- 149 
HERG            SSVRSGGAGGAGAPGAVVVDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGP 237 
mHCN2           ---------------------------------------SEEAGPA--G----------- 126 
MlotiK          ------------------------------------------------------------ 
                                                                             
mEAG            ------------------------------------------------------------ 
hEAG            ------------------------------------------------------------ 
HERG            GSPPRSAPGQLPSPRAHSLNPDASGSSCSLARTRSRESCASVRRASSADDIEAMRAGVLP 297 
mHCN2           ------------------------------------------------------------ 
MlotiK          ------------------------------------------------------------ 
                                                                             
              <---BD-N---> 
mEAG            ----------------------------------KFARLTRALTSSRGVLQQLAPSVQ-- 173 
hEAG            ----------------------------------KFARLTRALTSSRGVLQQLAPSVQ-- 173 
HERG            PPPRHASTGAMHPLRSGLLNSTSDSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDRE 357 
mHCN2           -----------------------------------EPRGSQASFLQRQFGALLQPGVN-- 149 
MlotiK          ------------------------------------------------------------ 
                                                                             
          |---------------S1--- 
mEAG            ------KGENVHKHSRLAEVLQLGSDILPQYKQEAPKTPPHIILHYCVFKTTWDWIILIL 227 
hEAG            ------KGENVHKHSRLAEVLQLGSDILPQYKQEAPKTPPHIILHYCVFKTTWDWIILIL 227 
HERG            IIAPKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTILHYSPFKAVWDWLILLL 417 
mHCN2           ---------------KFSLRMFGSQKAVEREQERVKSAGAWIIHPYSDFRFYWDFTMLLF 194 
MlotiK          --------------MSVLPFLRIYAPLNAVLAAPGLLAVAALTIPDMSGRSRLALAALLA 46 
                                .   :                            :       *:  
 
         --------|                 |---------S2---------| 
mEAG            TFYTAILVPYNVSFKTRQNN------------VAWLVVDSIVDVIFLVDIVLNFHT-TFV 274 
hEAG            TFYTAILVPYNVSFKTRQNN------------VAWLVVDSIVDVIFLVDIVLNFHT-TFV 274 
HERG            VIYTAVFTPYSAAFLLKETEEGPPATECGYACQPLAVVDLIVDIMFIVDILINFRT-TYV 476 
mHCN2           MVGNLIIIPVGITFFKDETT------------APWIVFNVVSDTFFLMDLVLNFRTGIVI 242 
MlotiK          VIWGAYLLQLAATLLKRRAG-----------------------VVRDRTPKIAIDVLAVL 83 
                 .    :     ::   .                          .      : : .   : 
 
      |-------S3--------| 
mEAG            GPAGEVISDPKLIRMNYLKTWFVIDLLSCLPYDVINAFENVDEVSAFMGDPGKIGFADQI 334 
hEAG            GPAGEVISDPKLIRMNYLKTWFVIDLLSCLPYDVINAFENVDEG---------------- 318 
HERG            NANEEVVSHPGRIAVHYFKGWFLIDMVAAIPFDLLIFGS--------------------- 515 
mHCN2           EDNTEIILDPEKIKKKYLRTWFVVDFVSSIPVDYIFLIVEKG------------------ 284 
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MlotiK          VPLAAFLLDGSPDWSLYCAVWLL------------------------------------- 106 
                     .: .       *   *::                                      
 
           |-------S4--------|       |------------S5--------- 
mEAG            PPPLEGRESQGISSLFSSLKVVRLLRLGRVARKLDHYIEYGAAVLVLLVCVFGLAAHWMA 394 
hEAG            -----------ISSLFSSLKVVRLLRLGRVARKLDHYIEYGAAVLVLLVCVFGLAAHWMA 367 
HERG            ----------GSEELIGLLKTARLLRLVRVARKLDRYSEYGAAVLFLLMCTFALIAHWLA 565 
mHCN2           -------------IDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTY 331 
MlotiK          ----------------------KPLRDSTFFPVLGRVLANEARNLIGVTTLFGVVLFAVA 144 
                                      : **   .   *.         *.     :    .    
 
         -------|                         |--- 
mEAG            CIWYSIGDYEIFDEDTKTIRNNSWLYQLALDIGTPYQFNGSGSGKWEGGPSKNSVYISSL 454 
hEAG            CIWYSIGDYEIFDEDTKTIRNNSWLYQLAMDIGTPYQFNGSGSGKWEGGPSKNSVYISSL 427 
HERG            CIWYAIGNMEQPHMDSRIG----WLHNLGDQIGKPYNSSGLG------GPSIKDKYVTAL 615 
mHCN2           DLASAVMRICNLISMMLLLCHWDGCLQFLVPMLQDFPSDCWVSINNMVNHSWSELYSFAL 391 
MlotiK          LAAYVIERDIQPEKFGSIP--------------------------------------QAM 166 
                     :                                                    :: 
 
         -----P----------|     |------------S6------------|  |------- 
mEAG            YFTMTSLTSVGFGNIAPSTDIEKIFAVAIMMIGSLLYATIFGNVTTIFQQMYANTNRYHE 514 
hEAG            YFTMTSLTSVGFGNIAPSTDIEKIFAVAIMMIGSLLYATIFGNVTTIFQQMYANTNRYHE 487 
HERG            YFTFSSLTSVGFGNVSPNTNSEKIFSICVMLIGSLMYASIFGNVSAIIQRLYSGTARYHT 675 
mHCN2           FKAMSHMLCIGYGRQAPESMTDIWLTMLSMIVGATCYAMFIGHATALIQSLDSSRRQYQE 451 
MlotiK          WWAVVTLSTTGYGDTIPQSFAGRVLAGAVMMSGIGIFGLWAG---ILATGFYQEVRR--- 220 
                : :.  :   *:*   *.:     ::   *: *   :.   *    :   :     :    
 
         αA’-------|   |-----αB’------|      |-αC’-|  |---αD’---| |- 
mEAG            MLNSVRDFLKLYQVPKGLSERVMDYIVSTWSMSRGIDTEKVLQICPKDMRADICVHLNRK 574 
hEAG            MLNSVRDFLKLYQVPKGLSERVMDYIVSTWSMSRGIDTEKVLQICPKDMRADICVHLNRK 547 
HERG            QMLRVREFIRFHQIPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGFPECLQADICLHLNRS 735 
mHCN2           KYKQVEQYMSFHKLPADFRQKIHDYYEHRYQG-KMFDEDSILGELNGPLREEIVNFNCRK 510 
MlotiK          ----------------------GDFVR------------------------------NWQ 228 
                                       ::                                  . 
 
        αE’-| |-αF’-||--αA---|  >β1->    >β2>      >-β3--> >β4-> 
mEAG            VFKEHPAFRLASDGCLRALAMEFQTVHCAPGDLIYHAGESVDSLCFVVSGSLEVIQDDEV 634 
hEAG            VFKEHPAFRLASDGCLRALAMEFQTVHCAPGDLIYHAGESVDSLCFVVSGSLEVIQDDEV 607 
HERG            LLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALYFISRGSIEILRGDVV 795 
mHCN2           LVASMPLFANADPNFVTAMLTKLKFEVFQPGDYIIREGTIGKKMYFIQHGVVSVLTKGNK 570 
MlotiK          LVAAVPLFQKLGPAVLVEIVRALRARTVPAGAVICRIGEPGDRMFFVVEGSVSVATPN-- 286 
                :.     *       :  :   ::     .*  : : *     : *:  * :.:   .   
   
     CNBD 
         >β5->  >β6>|--P---|      >β7>   >-β8->|---αB----||-------αC- 
mEAG            VAILGKGDVFGDVFWKEATLAQSCANVRALTYCDLHVIKRDALQKVLEFYTAFSHSFSRN 694 
hEAG            VAILGKGDVFGDVFWKEATLAQSCANVRALTYCDLHVIKRDALQKVLEFYTAFSHSFSRN 667 
HERG            VAILGKNDIFGEPLNLYARPGKSNGDVRALTYCDLHKIHRDDLLEVLDMYPEFSDHFWSS 855 
mHCN2           EMKLSDGSYFGEICLLTR--GRRTASVRADTYCRLYSLSVDNFNEVLEEYPMMRRAFETV 628 
MlotiK          PVELGPGAFFGEMALISG--EPRSATVSAATTVSLLSLHSADFQMLCSSSPEIAEIFRKT 344 
                   *. .  **:            . * * *   *  :    :  : .  . :   *    
 
        -------|<-BD-C1-->           <--BD-C2--> 
mEAG            LILTYNLRKRIVFRKISDVKREEEERMKRKNEAPLILPPDHPVRRLFQRFRQQKEARLAA 754 
hEAG            LILTYNLRKRIVFRKISDVKREEEERMKRKNEAPLILPPDHPVRRLFQRFRQQKEARLAA 727 
HERG            LEITFNLRDTNMIPGSPGS-TELEGGFSRQRKRKLSFR-----RRTDKDTEQPGEVSALG 909 
mHCN2           AIDRLDRIGKKNSILLHKVQHDLSSGVFNNQENAIIQEIVKYDREMVQQAELGQRVGLFP 688 
MlotiK          ALERRGAAASA------------------------------------------------- 355 
                     .                                                       
 
mEAG            ERGGRDLDDLDVEKGNALTDHTSANHSLVKASVVTVRESPATPVSFQAATTSTMSDHAKL 814 
hEAG            ERGGRDLDDLDVEKGNVLTEHASANHSLVKASVVTVRESPATPVSFQAASTSGVPDHAKL 787 
HERG            PGRAGAGPSSRGRPGGPWGESPSSGPSSPESSEDEGPGRSSSPLRLVPFSSPRPPGEPPG 969 
mHCN2           P------------------------PPPPQVTSAIATLQQAVAMSFCPQVARPLVGPLAL 724 
MlotiK          ------------------------------------------------------------ 
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mEAG            HAPGSECLGPKAVSCDPAK--RKGWARFKDACGKGEDWNKVSKAESMETLPERTKAPGEA 872 
hEAG            QAPGSECLGPKGGGGDCAK--RKSWARFKDACGKSEDWNKVSKAESMETLPERTKASGEA 845 
HERG            GEPLMEDCEKSSDTCNPLSGAFSGVSNIFSFWGDSRGRQYQELPRCPAPTPSLLNIPLSS 1029 
mHCN2           GSPRLVRRAPPGPLPPAAS--------------------PGPPAASPPAAPSSPRAPRTS 764 
MlotiK          ------------------------------------------------------------ 
                                                                             
mEAG            TLKKTDSCDSGITKSDLRLDNVGETRSPQDRSPILAEVKHSFYPIPEQTLQATVLEVKYE 932 
hEAG            TLKKTDSCDSGITKSDLRLDNVGEARSPQDRSPILAEVKHSFYPIPEQTLQATVLEVRHE 905 
HERG            PGRRPRGDVESRLDALQRQLNRLETRLSADMATVLQLLQRQMTLVPPAYSAVTTPGPGPT 1089 
mHCN2           PYGVPGS----------PATRVGPALPARRLSRASRPLSASQPSLPHGVPAPSPAASARP 814 
MlotiK          ------------------------------------------------------------ 
 
mEAG            LKEDIKALNAKMTSIEKQLSEILRILMSRGSAQSPQETGEISRPQSPESDRDIFGAS--- 989 
hEAG            LKEDIKALNAKMTNIEKQLSEILRILTSRRSSQSPQELFEISRPQSPESERDIFGAS--- 962 
HERG            STSPLLPVSPLPTLTLDSLSQVSQFMACEELPPGAPELPQEGPTRRLSLPGQLGALTSQP 1149 
mHCN2           ASSSTPRLGPAPTARTAAPSPDRRDSASPGAASGLDPLDSARSRLSSNL----------- 863 
MlotiK          ------------------------------------------------------------ 
                                                                             
mEAG            ---------- 
hEAG            ---------- 
HERG            LHRHGSDPGS 1159 
mHCN2           ---------- 
MlotiK          ---------- 
 
Multiple sequence alignment of C-linker (αA’-αF’), CNBD, BD-C1 and BD-C2 of mEAG 
 
 
|--αC’---| |--------αB’----------| |--- 
αD’----
| 
|-αE’| |--αF’-| |----αA----| >β1-> 
|----------αA’-----------| 
β2> >--β3--> >β4-> 
>β5-> β6> |------P------| >β7-> >-β8--> |-----αB-----| |--αC----| <-- 
BD-C1> <-BD-C2--> 
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Appendix II - mEAG full sequence 
LOCUS       NP_034730                989 aa            linear   ROD 13-MAR-2010 
DEFINITION  potassium voltage-gated channel subfamily H member 1 isoform 1 [Mus 
            musculus]. 
ACCESSION   NP_034730 
VERSION     NP_034730.1  GI:6754422 
 
CDS         1..989 
            /gene="Kcnh1" 
            /gene_synonym="M-eag; MGC124419; MGC124420" 
            /coded_by="NM_010600.2:137..3106" 
            /note="isoform 1 is encoded by transcript variant 1" 
            /db_xref="CCDS:CCDS15627.1" 
            /db_xref="GeneID:16510" 
            /db_xref="MGI:1341721" 
 
1 mtmaggrrgl vapqntflen ivrrsndtnf vlgnaqivdw pivysndgfc klsgyhraev 
       61 mqkssacsfm ygeltdkdtv ekvrqtfeny emnsfeilmy kknrtpvwff vkiapirneq 
      121 dkvvlflctf sditafkqpi eddsckgwgk farltralts srgvlqqlap svqkgenvhk 
      181 hsrlaevlql gsdilpqykq eapktpphii lhycvfkttw dwiililtfy tailvpynvs 
      241 fktrqnnvaw lvvdsivdvi flvdivlnfh ttfvgpagev isdpklirmn ylktwfvidl 
      301 lsclpydvin afenvdevsa fmgdpgkigf adqipppleg resqgisslf sslkvvrllr 
      361 lgrvarkldh yieygaavlv llvcvfglaa hwmaciwysi gdyeifdedt ktirnnswly 
      421 qlaldigtpy qfngsgsgkw eggpsknsvy isslyftmts ltsvgfgnia pstdiekifa 
      481 vaimmigsll yatifgnvtt ifqqmyantn ryhemlnsvr dflklyqvpk glservmdyi 
      541 vstwsmsrgi dtekvlqicp kdmradicvh lnrkvfkehp afrlasdgcl ralamefqtv 
      601 hcapgdliyh agesvdslcf vvsgsleviq ddevvailgk gdvfgdvfwk eatlaqscan 
      661 vraltycdlh vikrdalqkv lefytafshs fsrnliltyn lrkrivfrki sdvkreeeer 
      721 mkrkneapli lppdhpvrrl fqrfrqqkea rlaaerggrd lddldvekgn altdhtsanh 
      781 slvkasvvtv respatpvsf qaattstmsd haklhapgse clgpkavscd pakrkgwarf 
      841 kdacgkgedw nkvskaesme tlpertkapg eatlkktdsc dsgitksdlr ldnvgetrsp 
      901 qdrspilaev khsfypipeq tlqatvlevk yelkedikal nakmtsiekq lseilrilms 
      961 rgsaqspqet geisrpqspe sdrdifgas 
// 
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Appendix III - hCaM full sequence 
LOCUS       NP_005175                149 aa            linear   PRI 05-JUL-2010 
DEFINITION  calmodulin [Homo sapiens]. 
ACCESSION   NP_005175 
VERSION     NP_005175.2  GI:58218968 
 
CDS             1..149 
                     /gene="CALM3" 
                     /gene_synonym="CALM1; CALM2; PHKD; PHKD3" 
                     /coded_by="NM_005184.2:181..630" 
                     /db_xref="CCDS:CCDS33061.1" 
                     /db_xref="GeneID:808" 
                     /db_xref="HGNC:1449" 
                     /db_xref="HPRD:00243" 
                     /db_xref="MIM:114183" 
ORIGIN       
        1 madqlteeqi aefkeafslf dkdgdgtitt kelgtvmrsl gqnpteaelq dminevdadg 
       61 ngtidfpefl tmmarkmkdt dseeeireaf rvfdkdgngy isaaelrhvm tnlgekltde 
      121 evdemiread idgdgqvnye efvqmmtak 
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Appendix IV - Mass spectra of mEAG 552-724 proteolysis products
43 
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